High Flow Oxygen Therapy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The high flow oxygen therapy devices market size is projected to be USD 1.51 billion in 2025, USD 1.53 billion in 2026, and reach USD 1.72 billion by 2031, growing at a CAGR of 2.25% from 2026 to 2031. This report is Segmented by Product Type (High-Flow Nasal Cannulas, Breathing Circuits, and More), Device Mobility (Portable/Home HFNC Systems, and More), Humidification Technology (Active Heated, and More), Application (Acute Respiratory Failure, and More), End User (Hospitals & Clinics, and More), and Geography (North America, and More). Market Forecasts are Provided in Terms of Value (USD).

Global High Flow Oxygen Therapy Devices Market Trends and Insights

Growing COPD & Pneumonia Prevalence Elevating Non-Invasive Oxygen Demand

Global COPD cases stand near 392 million and continue to rise, putting sustained pressure on respiratory resources. Pneumonia admissions among U.S. seniors grew 18% between 2020 and 2024. Multicenter trials published in 2024 showed that high-flow therapy lowers intubation rates by up to 20% in acute hypoxemic failure. These outcomes encourage earlier use of nasal cannulas for COPD exacerbations, reinforcing recurring consumable demand. Home-use protocols that keep saturation above 90% now qualify for Medicare coverage, broadening patient access.

Post-COVID-19 Protocols Institutionalizing HFOT in Emergency Rooms & Wards

A 2025 survey of 320 U.S. hospitals revealed that 78% deploy high-flow systems as a first-line response when SpO₂ dips below 92%, almost doubling pre-pandemic adoption. Continued use reflects perceived infection-control benefits and reduced ICU transfers. European Respiratory Society guidelines issued in 2024 cemented high-flow oxygen as preferred therapy for immunocompromised patients. Infrastructure gaps linger, however: rural facilities in the United States Midwest experienced winter power outages that forced temporary shutdowns of high-flow equipment.

Post-Pandemic Equipment Overcapacity Depressing ASPs

U.S. hospitals held 2.8 high-flow units per ICU bed in 2024, more than double pre-pandemic norms. Surplus stock forced 15%-20% discounts on replacement tenders, squeezing margins. German university hospitals cited inventory leverage to win bids 18% below 2023 prices. Average stationary-system ASP dropped from USD 4,200 in 2023 to USD 3,500 in 2025, a direct drag on the high flow oxygen therapy devices market.

Other drivers and restraints analyzed in the detailed report include:

• Shift to Home High-Flow Therapy Supported by Reimbursement Expansion
• Technological Advances in Humidification & Smart Flow Monitoring
• High Electricity Dependence Limiting Adoption in Rural Hospitals

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

High-flow nasal cannulas generated 34.56% of 2025 sales, anchoring the high flow oxygen therapy devices market share within interfaces. Heated humidifiers, however, are growing at 5.26% and are pivotal to clinical comfort strategies. Fisher & Paykel’s MR850 became the U.S. ICU reference unit in 2025, appearing in 68% of surveyed protocols. Breathing circuits, water chambers, and probes form an annuity worth USD 180-240 per 30-day episode, a prop for the high flow oxygen therapy devices market size.

Accessories and full-face masks cover niche cohorts such as pediatric or claustrophobic patients. ResMed’s AirFit F30i found traction in European sleep centers treating overlap-syndrome cases. Portable kits bundled for home care compress margins 12%-15% versus hospital sales but simplify procurement for durable-medical-equipment suppliers. ISO 80601-2-90 testing obligations still favor incumbents with certified labs.

Stationary hospital systems controlled 61.21% of 2025 revenue, yet portable platforms are sprinting ahead at 6.54% CAGR as payers push for earlier discharge. Medicare’s 2025 rule change unlocked battery-powered units under 3 kg like Vapotherm’s Precision Flow Go. Portable runtime averages 4-6 hours at 50 L/min, limiting overnight independence. Hamilton’s T1 extends to 8 hours via smart blower modulation, but the USD 1,200 premium curtails volume.

Ventilator-integrated modules that toggle between invasive and high-flow modes grow 3.8% annually as ICU teams accelerate weaning. Stationary systems remain favored in surge planning because they deliver up to 80 L/min and tie into central gas outlets, though pandemic lessons spurred stockpiling of portables for field deployment.

Complete Report Scope:

• By Product Type
  • High-Flow Nasal Cannulas
  • Breathing Circuits
  • Heated Humidifiers
  • High-Flow Oxygen Masks
  • Accessories & Consumables
• By Device Mobility
  • Portable / Home HFNC Systems
  • Stationary Hospital Systems
  • Ventilator-Integrated HFOT Modules
• By Humidification Technology
  • Active Heated Humidification
  • Bubble Humidification
  • Passover / Passive Humidification
• By Application
  • Acute Respiratory Failure
  • COPD Management
  • Neonatal & Pediatric Care
  • Post-Operative & Palliative Care
  • Others (e.g., CO toxicity)
• By End User
  • Hospitals & Clinics
  • Home-Care Settings
  • Ambulatory & Long-Term Care Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 36.67% of 2025 revenue, buoyed by Medicare reimbursement and entrenched ICU protocols. Yet post-pandemic overcapacity trimmed stationary-system ASPs 17% between 2023 and 2025, limiting top-line lift. FDA cybersecurity rules elongate new-product cycles, slowing connected-device penetration.

In Europe, Carbon tariffs now steer hospitals toward EU-made systems, advantaging Draegerwerk and Air Liquide while inflating import costs. Asia-Pacific is the fastest-growing region at 4.32% CAGR as national insurance in China and India funds tier-2 respiratory upgrades. Rural grid instability, however, keeps high-flow use concentrated in urban hubs.

In Middle East & Africa and South America, Oil-funded Gulf projects mirror Western adoption curves, while Brazil’s 2024 directive integrated high-flow therapy into public hospitals. South African solar pilots stalled when battery costs exceeded plan. Currency volatility in Argentina reduced device imports 23% in 2025.

List of Companies Covered in this Report:

• Air Liquide
• Besmed Health Business
• BMC Medical
• Dragerwerk
• Eakin Healthcare
• Fisher & Paykel Healthcare
• Flexicare Medical
• Great Group Medical
• Hamilton Medical
• Koninklijke Philips
• Masimo
• Micomme Medical
• Resmed
• RMS Medical
• Smiths Group
• Teijin Pharma Ltd.
• Teleflex Medical
• Vapotherm
• Vincent Medical
• Vyaire Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support